Every year, excellent health-innovation companies from Europe, Asia, and Australia decide the United States and Canada are the growth market, and they are right. The market is enormous, it pays, and a North American reference customer changes a company's trajectory everywhere else. Then the entry stalls, for reasons that have little to do with the product.
The pattern is consistent. Regulatory clearance gets treated as market entry, when it is only the ticket to the parking lot. Home-market evidence gets discounted by American clinical buyers who want outcomes from systems that look like theirs. The distributor shortcut produces a year of meetings and no purchase orders. And procurement, the real boss fight, arrives with security reviews, compliance questionnaires, and committee dynamics that flatten teams who have never seen them.
Successful entries invert the usual order. Instead of hiring a country manager and hoping, they design the first three deals before designing the org chart. Pick a beachhead segment narrow enough to win. Land a pilot engineered to convert, with success criteria and a purchase path agreed in writing. Build the procurement package before the first security questionnaire arrives, not after. Then harvest the reference relentlessly: case study, site visits, peer-to-peer calls.
What that requires is not headcount. It is a working commercial engine with local credibility and local access: people who know which doors open, what the committee will ask, and how the deal actually closes. That connected, embedded entry is the work we do for international teams, and it is why our engagements start with the first deal rather than the first hire.